news - CarboHyde

Northwestern University and CarboHyde in arms against water contamination

Jul 18, 2023adminnewswater purification

It’s our pleasure to share that Will Dichtel’s lab at Northwestern University and CarboHyde just entered into a long-term research collaboration aiming to explore better Dr. Dichtel’s current research on the potential use of cyclodextrins as PFAS removers from drinking water.

Dr. Dichtel has been successfully working on various strategies to remove pollutants from drinking and wastewater. Now his expertise and concept will be supported by the cyclodextrin chemistry know-how of CarboHyde to create even more potent tools in this challenging application.

https://www.linkedin.com/posts/carbohyde_cyclodextrin-pfas-waterpurification-activity-7087002686151176193-6wJp?utm_source=share&utm_medium=member_desktop

CarboHyde Family and Friends at Eurocarb

Jul 11, 2023Tamas Sohajdanews

Our CSO, Milo Malanga, along with colleagues Kristof Felegyi, Szabolcs Beni and further collaborators from Semmelweis University are visiting Paris to learn about glycoscience at Eurocarb and initiate new collaborations.

Happy to meet you there!

33rd International Symposium on Pharmaceutical and Biomedical Analysis

Jul 5, 2023Tamas Sohajdanewsadvisory board, Szabolcs Beni

Core member of our advisory board, Szabolcs Béni from Semmelweis University, giving a talk about cyclodextrin and Sugammadex analysis at the 33rd International Symposium on Pharmaceutical and Biomedical Analysis, organized by Ankara University – Sibel A. OZKAN

Recording of the webinar Cyclodextrins in Biopharma available

Jun 26, 2023adminnewswebinar, Youtube

Dear Colleagues,

We are happy to share the recording of the first Roquette-CarboHyde joint webinar, Cyclodextrins in Biopharma is available on Youtube.

You can find the recording here: https://youtu.be/mHr-cc_JVEU

After watching the video, we would be grateful for your feedback about the event:

You will find the questionnaire here: https://docs.google.com/forms/d/e/1FAIpQLSfnsqlhqZDbjMvqqwhNGCU0Vgdl6APTbrKVL4tyXsKNChXOhA/viewform

the CarboHyde team

CarboHyde appoints Tamas Sohajda as CEO of the company

Jun 20, 2023adminnewscarbohyde, CEO

CarboHyde, a pharmaceutical company specializing in carbohydrate chemistry and innovative carbohydrate applications, today announced the appointment of its new CEO Tamas Sohajda, replacing the founder and former CEO, József Tóth. The reasons for the decision are captured in József’s personal memorandum below.

Dear colleagues, friends, and valued partners,

Today, I am writing to share an important announcement that marks a significant turning point in my life’s journey. After an incredible adventure at the helm of our beloved biotech startup CarboHyde, I have made the decision to retire from my role as CEO. I am stepping down from this position but will stay in the company as Chief Medical Officer.

It has become clear that dedicating myself both to a full-time consultant position at Semmelweis University and, meanwhile, leading CarboHyde is simply not feasible at the same time, as the expansion and development of the company demand an increasing amount of time, effort, and focus. As a result, I have come to the difficult decision to retire from my position as CEO in order to ensure that the company continues to thrive and reach its full potential under new leadership.

Words cannot express the deep gratitude and immense pride I feel as I reflect upon the extraordinary experiences we have shared throughout this incredible voyage. It has been an honor and a privilege to work alongside such remarkable individuals who have inspired me every single day.

Additionally, I would like to take a moment to express my utmost confidence in the capabilities of our incoming CEO. Tamás Sohajda, a brilliant and accomplished leader, will undoubtedly bring a fresh perspective and a wealth of expertise to guide our company into its next phase of growth. I have had the pleasure of working closely with Tamás and have witnessed firsthand his exceptional leadership qualities and strategic acumen. His deep understanding of the biotech industry, combined with his visionary thinking, will be invaluable assets as we steer CarboHyde toward new horizons. I have no doubt that Tamás will continue to drive our company towards even greater success.

In conclusion, I would like to express my deepest gratitude to each and every one of you.

With warm regards,

József Tóth

Founder and former CEO of CarboHyde

Carbohydrate Chronicles – A podcast about glycoscientists

Jun 20, 2023adminnewspodcast

We are happy to present Carbohydrate Chronicles, a podcast about Glycoscience and glycoscientists. In this show, via a series of interviews, we explore the world of carbohydrate science and innovation from the personal point of view hosted by Tamas Sohajda, a member of CarboHyde’s scientific team.

We find it important and essential to get familiar with the research and the researcher itself. In our series, we invite key opinion leaders of the glycoscience field both from academia and industry, to work on various angles of carbohydrates. Over 16 weeks, we will publish a new episode of 16 interviews altogether as part of our first season. All recordings will be available online at Apple Podcast, Spotify, YouTube, and Google Podcasts.

Learn more about the episodes here!

Cyclodextrins in Biopharma on June 21, 2023

May 30, 2023adminnewsevent, webinar

This free webinar series explores the present and future applications of cyclodextrins in biopharma through a series of educative sessions. It focuses on cyclodextrin uses in protein formulations (monoclonal antibodies), gene therapy, vaccines, and other biotech applications. The webinar includes an overview of the current market, three concise lectures by experts from Roquette and CarboHyde, and concludes with a moderated panel discussion featuring the speakers and key opinion leaders.

The audience can ask questions and participate in an open discussion about the challenges and possibilities of these innovative applications.

You can register here: Cyclodextrin in Biopharma (and more details about the program and experts)

Program

BioPharma Market Insights (15 min)
Elham Blouet, Regional Head Bio Pharma Technology, Roquette
Revolutionizing Gene Therapy: The Dynamic Duo of Cyclodextrins and Gene Delivery (40 min*)
Milo Malanga, CarboHyde
Unlock the potential of KLEPTOSE® Hydroxypropyl beta-cyclodextrin in biologics downstream process and formulation development (40 min*)
Peng Tao, BioPharma Research Manager, Roquette
Polysorbates versus KLEPTOSE® HPB Hydroxypropyl Beta-Cyclodextrin: Comparative Study on Stability & Antibody Stabilization (40 min*)
Hailong Zhang, Research Analytical Manager, Roquette
Panel discussion (45 min): Cyclodextrins-based formulations in Biopharma – current and future applications, advantages, and challenges

See more details here: Webinar: Cyclodextrins in Biopharma | Roquette

Renatus and Carbohyde sign MOU to co-develop novel cholesterol modulators for CNS disease applications.

May 26, 2023Tamas Sohajdanews

By combining Renatus’ proprietary cholesterol modulator and Carbohyde’s expertise in medicinal chemistry, the agreement aims to derive novel cholesterol modulators with improved CNS delivery.

Carbohyde is a pharma company specialized in developing carbohydrate-based APIs led by experts in carbohydrate chemistry, analysis, and pharmaceutical development. The company’s primary focus is neurodegenerative diseases, yet they have various programs in various unmet medical indications.

Renatus is specialized in developing cyclodextrin-based cholesterol modulators. The company’s chronic kidney disease program is currently in an IND-enabling stage, looking to complete the IND application by 2025. The company is developing pipelines for other cholesterol-driven diseases including CNS diseases.

“We have been following the technology of Renatus for a long time and built this relationship brick-by-brick. Our philosophy is that we can achieve much more with joint efforts, and this partnership will bring out the best of each partner, I am sure” as Tamas Sohajda, a member of CarboHyde’s scientific board shared his views on this strategic collaboration.

“Our proprietary cyclodextrin exhibits a superior safety profile over hydroxypropyl beta-cyclodextrin, which is currently in clinical trials for several cholesterol-driven diseases. Ototoxicity is a dose-limiting toxicity of the clinical-stage cyclodextrin and leads to irreversible hearing loss. It can induce kidney injury in some cases. However, our cyclodextrin injected at higher doses failed to induce such toxicity. Besides safety, it has shown greater efficacy in normalizing cholesterol homeostasis in some of the cholesterol-associated disease models we are exploring. I am very pleased to work with Carbohyde. We have a lot in common and share a common vision. The collaboration will significantly promote the application of our cyclodextrin for CNS diseases wherein cholesterol is causing trouble,” said Heegon Kim, CEO of Renatus.

University of Sydney and CarboHyde join forces in groundbreaking collaboration to combat natural toxins

May 16, 2023adminnews

University of Sydney, a leading innovator in researching natural toxins and poisons, and CarboHyde, a renowned expert in developing therapeutic carbohydrates are proud to announce their strategic partnership in the fight against natural toxins. This groundbreaking collaboration aims to advance research, develop effective solutions, and raise awareness about the detrimental impact of natural toxins on human health.

The world faces a growing threat from natural toxins, which can be found in various forms, including harmful algal blooms, venomous organisms, and poisonous plants. These toxins pose significant challenges to public health, wildlife, and ecosystems, demanding immediate attention and collaborative efforts to mitigate their harmful effects.

By combining their unique expertise, University of Sydney, led by Greg Neely and CarboHyde will work hand in hand to develop innovative technologies and approaches for neutralizing natural toxins and developing antidotes against poisoning or for prevention. “Our joint efforts will not only enhance the scientific understanding of these toxins but also pave the way for effective preventive measures and responsive strategies” – said Joseph Toth, CEO of CarboHyde. “Natural toxins present a complex and multifaceted challenge, requiring interdisciplinary solutions. This collaboration allows us to leverage our respective strengths and resources to address this pressing issue collaboratively. Together, we aim to develop comprehensive strategies that safeguard public health.” he added.

The partnership between the University of Sydney and CarboHyde signifies a milestone in the fight against natural toxins. By combining their research capabilities, technical expertise, and industry knowledge, these two partners are committed to making significant contributions to toxin detection, risk assessment, and effective mitigation strategies.

InnoGly COST Action Closing meeting

May 5, 2023adminnews

Tamas Sohajda represented us at the closing meeting of InnoGly a European COST Action aimed at facilitating networking and innovation of glycans in the field of cancer research, autophagy, immunity, and glycosaminoglycans. This was a fantastic experience and the start of several useful collaborations for the future.